Salmeterol, a novel, long-acting beta 2-adrenoceptor agonist: characterization of pharmacological activity in vitro and in vivo.
about
New combination bronchodilators for chronic obstructive pulmonary disease: current evidence and future perspectivesChronic systemic administration of salmeterol to rats promotes pulmonary beta(2)-adrenoceptor desensitization and down-regulation of G(s alpha)Subsensitivity of bronchodilator and systemic beta 2 adrenoceptor responses after regular twice daily treatment with eformoterol dry powder in asthmatic patientsCircadian rhythms in the pharmacokinetics and clinical effects of beta-agonist, theophylline, and anticholinergic medications in the treatment of nocturnal asthma.Effects of prior treatment with salmeterol and formoterol on airway and systemic beta 2 responses to fenoterolLung function efficacy and symptomatic benefit of olodaterol once daily delivered via Respimat® versus placebo and formoterol twice daily in patients with GOLD 2-4 COPD: results from two replicate 48-week studies.Indacaterol inhibits tumor cell invasiveness and MMP-9 expression by suppressing IKK/NF-κB activation.Salmeterol: a potent and long-acting inhibitor of inflammatory mediator release from human lungInhalation of beta 2 agonists impairs the clearance of nontypable Haemophilus influenzae from the murine respiratory tract.Different effects of salmeterol, formoterol and salbutamol on cholinergic responses in the ferret trachea.The interaction between salmeterol and beta 2-adrenoceptor agonists with higher efficacy on guinea-pig trachea and human bronchus in vitro.Salmeterol inhibition of mediator release from human lung mast cells by beta-adrenoceptor-dependent and independent mechanisms.Interaction and dose equivalence of salbutamol and salmeterol in patients with asthmaSystemic effects of formoterol and salmeterol: a dose-response comparison in healthy subjects.Systemic administration of beta2-adrenoceptor agonists, formoterol and salmeterol, elicit skeletal muscle hypertrophy in rats at micromolar doses.Dose equivalence and bronchoprotective effects of salmeterol and salbutamol in asthma.Time course and relative dose potency of systemic effects from salmeterol and salbutamol in healthy subjectsDrugs for asthmaInvestigations into factors determining the duration of action of the beta 2-adrenoceptor agonist, salmeterol.Comparison of the profiles of agonists as stimulants of the beta 3-adrenoceptor in vitro with their gastroprotective effects in the conscious rat.Extent of salmeterol-mediated reassertion of relaxation in guinea-pig trachea pretreated with aliphatic side chain structural analogues.Effects of agents which elevate cyclic AMP on guinea-pig eosinophil homotypic aggregationEffect of salmeterol on human nasal epithelial cell ciliary beating: inhibition of the ciliotoxin, pyocyanin.Randomised, double-blind, placebo-controlled crossover study to investigate different dosing regimens of olodaterol delivered via Respimat® in patients with moderate to severe persistent asthma.Twelve month comparison of salmeterol and salbutamol as dry powder formulations in asthmatic patients. European Study Group.Salmeterol, formoterol, and salbutamol in the isolated guinea pig trachea: differences in maximum relaxant effect and potency but not in functional antagonism.Beta-adrenoceptor subtypes and the opening of plasmalemmal K(+)-channels in trachealis muscle: electrophysiological and mechanical studies in guinea-pig tissueBeta-adrenoceptor subtypes and the opening of plasmalemmal K(+)-channels in bovine trachealis muscle: studies of mechanical activity and ion fluxes.Long-acting beta 2-agonists. Role in primary care asthma treatment.Systemic effects of salbutamol and salmeterol in patients with asthma.Pharmacotherapies for COPD.Treatment of mild chronic obstructive pulmonary disease.Role of beta-adrenoceptor signaling in skeletal muscle: implications for muscle wasting and disease.Clinicopharmacological profile of the fixed-dose combination of aclidinium bromide and formoterol fumarate in the management of chronic obstructive pulmonary disease.Cell membranes… and how long drugs may exert beneficial pharmacological activity in vivoA 4-week comparison of salmeterol and terbutaline in adult asthma.Molecular mechanisms for the persistent bronchodilatory effect of the beta 2-adrenoceptor agonist salmeterolAgonist-specific patterns of beta 2-adrenoceptor responses in human airway cells during prolonged exposure.Sir David Jack: an extraordinary drug discoverer and developer.Airway smooth muscle relaxation.
P2860
Q27024384-061857DB-C6EE-4629-8F0E-61A50A3C2F66Q28360183-8927A3C9-FA1E-43E1-BC66-14A903970580Q33604886-6843C0E9-64E5-4123-A50C-7E2E723BC641Q33747962-B2C578AF-CC71-4013-A89D-974460403E6BQ33775366-F5A7CAF9-9463-42A1-85FF-D938B20CFEFDQ33890178-B56C6BBC-DB2F-435F-BE3D-C3B19B47C69AQ34092070-14FBB729-3BD9-49FA-99A4-62A394963E53Q34574302-633070C3-C400-4086-BC88-F4333E3EC860Q34590657-10F076DD-70E3-44B1-86DD-AD73D867CE6BQ34793042-3CBF1030-4010-4F66-BB30-5C6F056B542BQ34793535-BA93C95C-9C92-44B9-88FF-CC91F0A8BBF7Q35027302-76891A34-3F1A-4275-8A5D-8DE71AEA387BQ35187262-71532EB3-E9FC-461F-871B-DC70DE7A7216Q35533937-E331BC2C-D93E-4EEF-858E-3E6ABB28A6F9Q35545362-EC15C0AF-9950-4274-B2B3-DC5E68701268Q35563253-3E5C7737-A10B-429D-96CA-C17927189D2CQ35563595-26E34238-5534-49C6-A22F-118665F076CEQ35566594-B5AB1349-893F-4B8E-89C4-6FE558C1B717Q35871413-94A62150-B71E-4DEF-99E9-EF819521A471Q35873282-53FCC1AB-8072-4C4B-B3F8-27F93C2E8468Q35873966-C9C06BD8-020C-42C0-99CB-83D9B44500C0Q35874181-718B4CCE-681D-4A7E-9A11-AE65926F0776Q35874799-069B4B59-313E-4ABE-8E9B-B2F393D5DFF7Q35875281-B046C6BE-82C5-407D-A173-B4B903FF69A2Q36274692-9DC6FFF8-D987-48B4-A9E0-4210670BB609Q36280784-83849878-30D7-4231-8C08-CBB0D14254D3Q36329734-69E58546-3CFF-4D2C-AB1B-97E77FB993C5Q36329767-54F6A5D4-A07F-4C97-961D-8AE84BC9D37CQ36479702-E954C642-3858-4EE8-BF95-AE90813D3E63Q36573494-D2B937F1-28A0-4AFB-8568-910F26D330F4Q36843717-298345FE-642D-4E9E-9F12-84F5BA1C7ED5Q37115902-9DCB64FC-FCD5-4CC4-9B9E-FE00D02E7E24Q37129351-DD99EABD-4869-491D-83A9-5F8D6500FCC4Q38371305-3BDA4102-8638-4AB8-B6C0-14E88A4877D7Q38822818-5DE16B5E-1AC1-4DA3-A7D4-5D99350995A2Q39473482-246843CF-C308-455D-B38C-4850B6CAD02BQ39826205-4DDD75C7-8E47-4265-90DD-6A4CF1572DA8Q39832616-38099214-6218-4561-AD66-6EA66F701219Q40086536-D27C885D-635A-4D65-9A8B-B419C7A51163Q40419425-F53B6665-C31E-438B-9F2B-4E9084AABE5C
P2860
Salmeterol, a novel, long-acting beta 2-adrenoceptor agonist: characterization of pharmacological activity in vitro and in vivo.
description
1991 nî lūn-bûn
@nan
1991年の論文
@ja
1991年論文
@yue
1991年論文
@zh-hant
1991年論文
@zh-hk
1991年論文
@zh-mo
1991年論文
@zh-tw
1991年论文
@wuu
1991年论文
@zh
1991年论文
@zh-cn
name
Salmeterol, a novel, long-acti ...... activity in vitro and in vivo.
@en
Salmeterol, a novel, long-acti ...... activity in vitro and in vivo.
@nl
type
label
Salmeterol, a novel, long-acti ...... activity in vitro and in vivo.
@en
Salmeterol, a novel, long-acti ...... activity in vitro and in vivo.
@nl
prefLabel
Salmeterol, a novel, long-acti ...... activity in vitro and in vivo.
@en
Salmeterol, a novel, long-acti ...... activity in vitro and in vivo.
@nl
P2093
P2860
P1476
Salmeterol, a novel, long-acti ...... activity in vitro and in vivo.
@en
P2093
Brittain RT
Coleman RA
Sheldrick KE
Skidmore IF
P2860
P304
P356
10.1111/J.1476-5381.1991.TB12486.X
P407
P577
1991-11-01T00:00:00Z